Allogene data for ALLO-329 autoimmune CAR T, expects initial Phase 1 RESOLUTION data in June 2026
Allogene Therapeutics publishes Nature Communications data for ALLO-329 autoimmune CAR T, expects initial Phase 1 RESOLUTION data in June 2026
- ALLO-329 is a dual-targeted CD19/CD70 allogeneic CAR T candidate being developed for autoimmune disease.
- Company reiterates initial Phase 1 RESOLUTION trial data expected in June 2026, with a further update anticipated by year-end 2026.
- Allogene Therapeutics previously priced $175 million underwritten common stock offering at $2.00 per share.
- Offering comprises 87.5 million common shares, with 30-day option for underwriters to buy 13.125 million more.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.